DuChemBIO Co.,Ltd. announced that it expects to receive KRW 1.299994 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm
August 12, 2018
Share
DuChemBIO Co.,Ltd. (XKON:A176750) announced a private placement of 134,020 convertible preferred shares at a price of KRW 9,700 per share for gross proceeds of KRW 1,299,994,000 on August 13, 2018. The transaction will include participation from new investor, NH Investment & Securities Co., Ltd., Investment Arm. The shares are issued through a third party allotment method. The shares have a face value of KRW 500 per share. The shares are issued at a premium of 18.4%. The preferred stock is convertible into common shares of the company and the conversion period is from August 22, 2018 to August 22, 2028. Post the closing, the number of preferred shares will increase from 644,445 to 778,465. The payment date is August 21, 2018. The transaction has been approved by the board of directors of the company.
DuChemBio Co Ltd is a Korea-based company principally engaged in the manufacture and sale of radiopharmaceuticals. The Company is engaged in the manufacture and sale of diagnostic radiopharmaceuticals such as radiopharmaceuticals for the diagnosis of Parkinson's disease, radiopharmaceuticals for the diagnosis of Alzheimer's disease, and radiopharmaceuticals for the diagnosis of brain tumors. In addition, the Company is engaged in the sale of computed tomography (CT) contrast agents and other products.